Cargando…

Comparison of Bevacizumab and Aflibercept for Suppression of Angiogenesis in Human Retinal Microvascular Endothelial Cells

Bevacizumab (Avastin) is a vascular endothelial growth factor (VEGF) inhibitor that is widely used for aggressive posterior retinopathy of prematurity (APROP). Its use is associated with multiple adverse effects. Aflibercept (Eylea) is a VEGFR-1 analogue that is approved for ocular use, but its effi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yazdanyar, Amirfarbod, Cai, Charles L., Aranda, Jacob V., Shrier, Eric, Beharry, Kay D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10383229/ https://www.ncbi.nlm.nih.gov/pubmed/37513851 http://dx.doi.org/10.3390/ph16070939

Ejemplares similares

Dose Response of Bumetanide on Aquaporins and Angiogenesis Biomarkers in Human Retinal Endothelial Cells Exposed to Intermittent Hypoxia
por: Guzel, Sibel, et al.
Publicado: (2021)

Ocular Adverse Effects of Intravitreal Bevacizumab Are Potentiated by Intermittent Hypoxia in a Rat Model of Oxygen-Induced Retinopathy
por: Tan, Jeffrey J., et al.
Publicado: (2017)

Bumetanide Suppression of Angiogenesis in a Rat Model of Oxygen-Induced Retinopathy
por: Guzel, Sibel, et al.
Publicado: (2020)

Animal models of diabetic retinopathy
por: Quiroz, Jose, et al.
Publicado: (2021)

Bevacizumab versus ziv-aflibercept in branch retinal vein occlusion
por: Braimah, Imoro Z, et al.
Publicado: (2019)

Actions of bevacizumab and ranibizumab on microvascular retinal endothelial cells: similarities and differences
por: Deissler, Heidrun L, et al.
Publicado: (2012)

Coenzyme Q10 and Fish Oil Supplementation for Reducing Retinal Oxidative Stress in a Rat Model
por: Siddiqui, Faisal, et al.
Publicado: (2023)

Effects of Ranibizumab, Bevacizumab, and Aflibercept on Senescent Retinal Pigment Epithelial Cells
por: Chae, Jae-Byoung, et al.
Publicado: (2018)

Comparative Effects of Coenzyme Q10 or n-3 Polyunsaturated Fatty Acid Supplementation on Retinal Angiogenesis in a Rat Model of Oxygen-Induced Retinopathy
por: Beharry, Kay D., et al.
Publicado: (2018)

Comparison of the Efficacy of Intravitreal Aflibercept and Bevacizumab for Macular Edema Secondary to Branch Retinal Vein Occlusion
por: Wang, Jia-Kang, et al.
Publicado: (2016)

Role of Phospholipid Transfer Protein in High-Density Lipoprotein– Mediated Reverse Cholesterol Transport
por: Yazdanyar, Amirfarbod, et al.
Publicado: (2011)

Safety profiles of anti-VEGF drugs: bevacizumab, ranibizumab, aflibercept and ziv-aflibercept on human retinal pigment epithelium cells in culture
por: Malik, Deepika, et al.
Publicado: (2014)

Effect of bevacizumab (Avastin™) on mitochondrial function of in vitro retinal pigment epithelial, neurosensory retinal and microvascular endothelial cells
por: Luthra, Saurabh, et al.
Publicado: (2013)

Aflibercept Suppression of Angiopoietin-2 in a Rabbit Retinal Vascular Hyperpermeability Model
por: Lange, Claudia, et al.
Publicado: (2023)

Aflibercept Suppression of Angiopoietin-2 in a Rabbit Retinal Vascular Hyperpermeability Model
por: Lange, Claudia, et al.
Publicado: (2023)

Comparison of aflibercept and bevacizumab in the treatment of type 1 retinopathy of prematurity
por: Riazi-esfahani, Hamid, et al.
Publicado: (2021)

Formulation Stabilization and Disaggregation of Bevacizumab, Ranibizumab and Aflibercept in Dilute Solutions
por: Giannos, Steven A., et al.
Publicado: (2018)

Analysis of the retinal capillary plexus layers in a murine model with diabetic retinopathy: effect of intravitreal injection of human CD34(+) bone marrow stem cells
por: Cheung, Kong Wa, et al.
Publicado: (2021)

SYSTEMIC PHARMACOKINETICS AND PHARMACODYNAMICS OF INTRAVITREAL AFLIBERCEPT, BEVACIZUMAB, AND RANIBIZUMAB
por: Avery, Robert L., et al.
Publicado: (2017)

KLF4 Promotes Angiogenesis by Activating VEGF Signaling in Human Retinal Microvascular Endothelial Cells
por: Wang, Yinan, et al.
Publicado: (2015)

Curcumin suppresses intestinal microvascular endothelial cells invasion and angiogenesis induced by activated platelets
por: Xu, Su, et al.
Publicado: (2019)

Conversion to aflibercept for diabetic macular edema unresponsive to ranibizumab or bevacizumab
por: Lim, Laurence S, et al.
Publicado: (2015)

Intravitreal aflibercept versus bevacizumab for treatment of myopic choroidal neovascularization
por: Wang, Jia-Kang, et al.
Publicado: (2018)

Fusion proteins for treatment of retinal diseases: aflibercept, ziv-aflibercept, and conbercept
por: de Oliveira Dias, João Rafael, et al.
Publicado: (2016)

Comparison of intravitreal ziv-aflibercept and bevacizumab monotherapy in treatment-naive polypoidal choroidal vasculopathy
por: Singh, Sumit Randhir, et al.
Publicado: (2019)

Fate of the Fc fusion protein aflibercept in retinal endothelial cells: competition of recycling and degradation
por: Deissler, Heidrun L., et al.
Publicado: (2018)

Topical versus subconjunctival anti-vascular endothelial growth factor therapy (Bevacizumab, Ranibizumab and Aflibercept) for treatment of corneal neovascularization
por: Al-Debasi, Tariq, et al.
Publicado: (2017)

Aflibercept monotherapy versus aflibercept with targeted retinal laser to peripheral retinal ischemia for diabetic macular oedema (LADAMO)
por: Cornish, E. E., et al.
Publicado: (2023)

CHANGES IN PLASMA VASCULAR ENDOTHELIAL GROWTH FACTOR LEVEL AFTER INTRAVITREAL INJECTION OF BEVACIZUMAB, AFLIBERCEPT, OR RANIBIZUMAB FOR DIABETIC MACULAR EDEMA
por: Hirano, Takao, et al.
Publicado: (2018)

Macular Oedema in Idiopathic Macular Telangiectasia Type 1 Responsive to Aflibercept but Not Bevacizumab
por: Shibeeb, O'Sam, et al.
Publicado: (2014)

Hydrodynamic Radii of Ranibizumab, Aflibercept and Bevacizumab Measured by Time-Resolved Phosphorescence Anisotropy
por: Hirvonen, Liisa M., et al.
Publicado: (2016)

Switch to aflibercept or ranibizumab after initial treatment with bevacizumab in eyes with neovascular AMD
por: Waizel, Maria, et al.
Publicado: (2017)

Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab
por: Hamid, Mohamed A., et al.
Publicado: (2021)

One-year outcomes of Aflibercept for refractory diabetic macular edema in Bevacizumab nonresponders
por: Salimi, Ali, et al.
Publicado: (2021)

Exacerbation of pigment epithelial detachment following aflibercept: A case of bevacizumab rescue()
por: Davoudi, Samaneh, et al.
Publicado: (2021)

Monthly Alternating Injections of Aflibercept and Bevacizumab for Neovascular Age-Related Macular Degeneration
por: Lee, Junyeop, et al.
Publicado: (2022)

Renal biomarkers of acute kidney injury in response to increasing intermittent hypoxia episodes in the neonatal rat
por: Zangaladze, Anano, et al.
Publicado: (2021)

Cost Effectiveness of Ranibizumab vs Aflibercept vs Bevacizumab for the Treatment of Macular Oedema Due to Central Retinal Vein Occlusion: The LEAVO Study
por: Pennington, Becky, et al.
Publicado: (2021)

Endothelial Cell Phenotypes are Maintained During Angiogenesis in Cultured Microvascular Networks
por: Motherwell, Jessica M., et al.
Publicado: (2018)

Intraoperative Retinal Changes May Predict Surgical Outcomes After Epiretinal Membrane Peeling
por: Mukkamala, Lekha K., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_mhvo2ej6h0f2ccj2hfgch5q3ph